positiv finde ich, dass die wandlung von optionen m.M. nach teilweise (nämlich zu 40%) vom (wirtschaftlichen) erfolg des unternehmens abhängig gemacht wird: 20% bei zulassung von Genasense; weitere 20%, wenn marktkapitalisierung > 509 Mio $... [...] Grant of Restricted Stock Units to Raymond P. Warrell, Jr. M. D., Chairman and Chief Executive Officer, Loretta M. Itri, M.D., W. Lloyd Sanders, Senior Vice President and Chief Operating Officer and Gary Siegel, Vice President, Finance
On August 26, 2009, the Compensation Committee of the Board of Directors awarded the following grants of restricted stock units pursuant to the Company’s 2009 Stock Incentive Plan, and pursuant to the Company’s option exchange program. The 2009 Stock Incentive Plan and accompanying option exchange program were approved by the Company’s stockholders at the Annual Meeting of Genta Stockholders on August 26, 2009.
Raymond P. Warrell, Jr. M. D., Chairman and Chief Executive Officer exchanged all of his outstanding options that had been granted pursuant to the Company’s 1998 Stock Incentive Plan, as amended. In exchange for these options, on August 31, 2009, Dr. Warrell was granted 26,474,679 shares of restricted stock units. These restricted stock units will vest as follows: Sixty percent (60%) of the Initial Grant amount, or 15,884,807 shares shall vest as follows: 25%, or 3,971,202 shares, on the grant date, with the balance of the 60%, or 11,913,605 shares, vesting in thirteen (13) equal portions on quarterly anniversaries from the grant date, so as to be fully vested on December 31, 2012. Twenty percent (20%) of the Initial Grant or 5,294,936 shares, shall vest on the date the Company has received notice from the U.S. Food and Drug Administration or from the European Medicines Agency that Genasense® has been approved for marketing by U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMEA). Twenty percent (20%) of the Initial Grant, or 5,294,936 shares, shall vest on the date when the market capitalization of the Company first exceeds ten (10) times the market capitalization value as of the Initial Grant date. The market capitalization value shall be calculated for the grant date and for the vesting date using a standard measure of the Company’s daily closing stock price multiplied by the number of shares issued and outstanding on each of those dates. The market capitalization of Genta Incorporated on the Initial Grant date of August 31, 2009 was $50,869,855.58 determined by multiplying the closing stock price of $0.38, as reported by Bloomberg.com, by the number of Genta shares issued and outstanding of 133,868,041, as determined by The Company. [...]
Quelle: http://www.implu.com/releases/2009/20090911/30448/implu_viewer andere auffassungen/meinungen willkommen! btw: ende august gab es also rund 51 Mio aktien ;-) |
Thread abonnieren
